WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

PURPOSE: Despite recent advances, approximately 50% of patient with metastatic melanoma eventually succumb to the disease. Patients with melanomas harboring a BRAF mutation (BRAF(Mut)) have a worse prognosis than those with wildtype (BRAF(WT)) tumors. Unexpectedly, interim AVAST-M Phase III trial da...

Descripción completa

Detalles Bibliográficos
Autores principales: Coupe, Nicholas, Guo, Lina, Bridges, Esther, Campo, Leticia, Espinosa, Olivia, Colling, Richard, Marshall, Andrea, Nandakumar, Ashwin, van Stiphout, Ruud, Buffa, Francesca M., Corrie, Pippa G., Middleton, Mark R., Macaulay, Valentine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060292/
https://www.ncbi.nlm.nih.gov/pubmed/36539575
http://dx.doi.org/10.1007/s13402-022-00757-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060292/
https://www.ncbi.nlm.nih.gov/pubmed/36539575
http://dx.doi.org/10.1007/s13402-022-00757-7

Ejemplares similares